Article

Immunosuppression and Outcomes in Acute Myeloid Leukemia

2021-09-06

Abstract excerpt

Acute myeloid leukemia (AML) patients rarely have long first remissions (> 5 years) after standard-of-care chemotherapy, unless classified as favorable risk at presentation. Identification of the mechanisms responsible for long vs. more typical, short remissions may help to define prognostic determinants for chemotherapy responses. Using exome sequencing, RNA sequencing and functional immunologic studies, we chara...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8d421ec3-d5b8-564a-9129-9fcafb35270c
DOI: 10.1101/2021.09.03.458879

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunosuppression and Outcomes in Acute Myeloid LeukemiaDOI 10.1101/2021.09.03.458879Read

Dynamics of Leukemic Blast and Immune Cell Populations in Acute Myeloid LeukemiaSemantic proximity Read

Bone marrow tumor microenvironment profiling predicts distinct immunosuppressive phenotypes and immunotherapy potential in AML patientsSemantic proximity Read

Evolving treatment strategies in patients with high-risk acute myeloid leukemia.Semantic proximity Read

Single-cell data revealed the function of natural killer cells and macrophage cells in chemotherapy tolerance in acute myeloid leukemiaSemantic proximity Read

AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AMLSemantic proximity Read

The interaction between common genetic mutations in AML and the immune landscape: mechanisms and implications for immune responseSemantic proximity Read

High percentage of bone marrow CD8+ tissue-resident-like T cells predicts inferior survival in patients with acute myeloid leukemiaSemantic proximity Read

Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001-2013.Semantic proximity Read

Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse GeneticsSemantic proximity Read

The cellular state space of AML unveils novel <i>NPM1</i> subtypes with distinct clinical outcomes and immune evasion propertiesSemantic proximity Read

Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value.Semantic proximity Read

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?Semantic proximity Read